$434.37 Million in Sales Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter

Equities analysts expect BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report sales of $434.37 million for the current quarter, Zacks reports. Nine analysts have issued estimates for BioMarin Pharmaceutical’s earnings, with the highest sales estimate coming in at $456.42 million and the lowest estimate coming in at $413.30 million. BioMarin Pharmaceutical reported sales of $476.78 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 8.9%. The company is scheduled to announce its next earnings results on Thursday, November 4th.

On average, analysts expect that BioMarin Pharmaceutical will report full-year sales of $1.86 billion for the current financial year, with estimates ranging from $1.83 billion to $1.88 billion. For the next year, analysts expect that the company will report sales of $2.15 billion, with estimates ranging from $1.84 billion to $2.28 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for BioMarin Pharmaceutical.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Tuesday, July 27th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.18. The company had revenue of $501.69 million during the quarter, compared to the consensus estimate of $448.84 million. BioMarin Pharmaceutical had a return on equity of 3.34% and a net margin of 43.68%.

BMRN has been the subject of several research reports. Jefferies Financial Group initiated coverage on BioMarin Pharmaceutical in a research note on Thursday, July 29th. They set a “buy” rating and a $112.00 price target for the company. Zacks Investment Research downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating and set a $81.00 price target for the company. in a research note on Tuesday, August 3rd. SVB Leerink reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday. Piper Sandler lifted their price target on BioMarin Pharmaceutical from $112.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday, July 29th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and set a $88.00 price target on shares of BioMarin Pharmaceutical in a research note on Tuesday, September 7th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $101.39.

Shares of NASDAQ:BMRN traded down $1.81 during midday trading on Tuesday, hitting $76.17. 791,027 shares of the stock were exchanged, compared to its average volume of 1,119,303. The stock has a market cap of $13.97 billion, a P/E ratio of 17.76, a PEG ratio of 15.81 and a beta of 0.53. The company has a current ratio of 5.32, a quick ratio of 3.71 and a debt-to-equity ratio of 0.25. BioMarin Pharmaceutical has a twelve month low of $71.65 and a twelve month high of $92.57. The company has a 50 day moving average price of $78.93 and a 200-day moving average price of $78.90.

A number of hedge funds have recently made changes to their positions in the stock. Dodge & Cox grew its holdings in BioMarin Pharmaceutical by 19.0% in the 2nd quarter. Dodge & Cox now owns 14,102,097 shares of the biotechnology company’s stock valued at $1,176,679,000 after buying an additional 2,247,789 shares during the period. Ameriprise Financial Inc. grew its holdings in BioMarin Pharmaceutical by 43.0% in the 1st quarter. Ameriprise Financial Inc. now owns 6,233,335 shares of the biotechnology company’s stock valued at $470,682,000 after buying an additional 1,873,040 shares during the period. Parnassus Investments CA grew its holdings in BioMarin Pharmaceutical by 76.8% in the 1st quarter. Parnassus Investments CA now owns 2,684,874 shares of the biotechnology company’s stock valued at $202,735,000 after buying an additional 1,165,923 shares during the period. JPMorgan Chase & Co. grew its holdings in BioMarin Pharmaceutical by 29.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,755,379 shares of the biotechnology company’s stock valued at $313,348,000 after buying an additional 847,367 shares during the period. Finally, California Public Employees Retirement System grew its holdings in BioMarin Pharmaceutical by 40.5% in the 2nd quarter. California Public Employees Retirement System now owns 1,296,440 shares of the biotechnology company’s stock valued at $108,175,000 after buying an additional 373,727 shares during the period. 94.44% of the stock is owned by hedge funds and other institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.

See Also: Does a trade war provide a risk to the global economy?

Get a free copy of the Zacks research report on BioMarin Pharmaceutical (BMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.